Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 3Active not recruiting 1

Sponsor Class

INDUSTRY 12OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Ovarian Neoplasms 2Endometrial Neoplasms 2Fallopian Tube Neoplasms 1

Interventions

pembrolizumab 603Cyclophosphamide 545Magnetic Resonance Spectroscopy 527Radiotherapy 513Specimen Handling 505Nivolumab 411Cisplatin 381Carboplatin 369Biopsy 305Blood Specimen Collection 304Radiosurgery 290Paclitaxel 281Gemcitabine 271Surveys and Questionnaires 269Standard of Care 267fludarabine 263Drug Therapy 263Dexamethasone 263Bevacizumab 252venetoclax 251Oxaliplatin 209Capecitabine 199Rituximab 198Radiation 191Ipilimumab 188Fluorouracil 188durvalumab 185Doxorubicin 178Etoposide 177atezolizumab 172

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × mirvetuximab soravtansine × 1 year × Clear all
NCT05887609 2026-06-04

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

University of Colorado, Denver

Phase 2 Recruiting
53 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03835819 2026-06-01

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
18 enrolled 17 charts
Gynecologic

Endometrial Neoplasms

NCT04606914 2025-09-08

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

University of Alabama at Birmingham

Phase 2 Recruiting
70 enrolled
Gynecologic

Ovarian Neoplasms

NCT03832361 2025-07-18

Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

Yale University

Phase 2 Recruiting
50 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡